Back to search results

Noninvasive Brain Stimulation for Adult Amblyopia

This study is investigating if a non-invasive brain stimulation technique, called High Frequency Transcranial Random Noise Stimulation, can help improve vision in adults with amblyopia (often called "lazy eye"). Participants will receive either the active stimulation or a "sham" (inactive) stimulation over five consecutive days. Researchers will measure changes in your visual sharpness (Crowded Visual Acuity), depth perception (Stereo Acuity), and how sensitive your brain is to light (Phosphene Threshold) to see if the treatment is effective. You may be able to join if you are an adult between 18 and 55 years old with a diagnosis of amblyopia in one or both eyes. The study aims to enroll 60 participants.

Study design
This is a randomized controlled trial, meaning participants will be randomly assigned to receive either the active treatment or a sham treatment. The study plans to enroll 60 participants.
What's involved
Participants will receive daily stimulation for five consecutive days. Visual assessments will be conducted before, during, and after treatment, and at 24-hour, 72-hour, and 10-day follow-up points.
Compensation
Not stated in the trial record.
Follow-up
Participants will have follow-up assessments at 24 hours, 72 hours, and 10 days after the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06712849

Noninvasive Brain Stimulation in Adult Amblyopia

Recruiting
NAAges 18–55InterventionalTreatment
Midwestern University
~60 participants
Updated 2024-12-12 on ClinicalTrials.gov
What's tested:Sham Transcranial Random Noise StimulationHigh Frequency Transcranial Random Noise Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Crowded Visual Acuity
Measured over Pre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).
+5 more outcomes measured

Conditions

Amblyopia

Explore related trials

Amblyopia

Where it's being run

1 sites across 1 states
Illinois1

Who to contact

Arijit Chakraborty, PhD
[email protected]
630-960-3172
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults between 18 and 55 years of age
Formal diagnosis of amblyopia in one or both eyes of any etiology

Exclusion

History of optic nerve disease, including glaucoma and optic neuritis
History of neurological conditions, including demyelinating disease or stroke
Presence of metal or electronic implants in or on the body, including pacemakers
Taking medications that can affect normal neurological function, including antipsychotics, antiepileptics, and opioids

What this trial measures

  • Crowded Visual AcuityPre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in crowded visual acuity is measured in LogMAR from baseline.

  • Stereo AcuityPre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in stereo acuity is measured in arc seconds from baseline.

  • Phosphene ThresholdPre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in phosphene threshold (%) from baseline.

  • Global Motion PerceptionPre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in global motion perception coherence threshold (%) from baseline.

  • Form Pattern RecognitionPre- and post-treatment (Days 1-5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in form pattern recognition coherence threshold (%) from baseline.

  • Pattern-reversal Visual Evoked Potentials (pVEP)Pre-treatment (Day 1); post-treatment (Day 5); 24-hour follow-up (Day 6); 72-hour follow-up (Day 8); and 10-day follow-up (Day 15).

    A change in N75-P100 amplitudes and P100 latencies from baseline.